Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

(RTTNews) - Myriad Genetics, Inc. (MYGN) announced new interim data from the MONSTAR-SCREEN-3 study, showcasing the high sensitivity and pan-cancer applicability of its Precise Minimal Residual ...

Myriad Genetics, Inc. MYGN recently announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The latest ...

SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight ...

Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

Adela's tissue-agnostic MRD test has been clinically validated to predict and surveil for recurrence in patients with head & neck cancer, regardless of HPV status The test identified recurrences in ...

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...